A detailed history of Cape Investment Advisory, Inc. transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Cape Investment Advisory, Inc. holds 350 shares of RVNC stock, worth $899. This represents 0.0% of its overall portfolio holdings.

Number of Shares
350
Previous 447 21.7%
Holding current value
$899
Previous $1.15 Million 58.14%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.57 - $2.57 $249 - $249
-97 Reduced 21.7%
350 $1.82 Million
Q3 2023

Nov 06, 2023

SELL
$11.47 - $25.07 $4,932 - $10,780
-430 Reduced 49.03%
447 $5.13 Million
Q1 2023

Oct 12, 2023

BUY
$18.36 - $35.27 $16,101 - $30,931
877 New
877 $28.2 Million

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Cape Investment Advisory, Inc. Portfolio

Follow Cape Investment Advisory, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cape Investment Advisory, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cape Investment Advisory, Inc. with notifications on news.